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Abstract
Background Percutaneous anchoring of femoral amputa-
tion prostheses using osseointegrating titanium implants
has been in use for more than 25 years. The method offers
considerable advantages in daily life compared with con-
ventional socket prostheses, however long-term success
might be jeopardized by implant-associated infection,
especially osteomyelitis, but the long-term risk of this
complication is unknown.
Questions/Purposes (1) To quantify the risk of
osteomyelitis, (2) to characterize the clinical effect of
osteomyelitis (including risk of implant extraction and
impairments to function), and (3) to determine whether
common patient factors (age, sex, body weight, diabetes,
and implant component replacements) are associated with
osteomyelitis in patients with transfemoral amputations
treated with osseointegrated titanium implants.
Methods We retrospectively analyzed our first 96 patients
receiving femoral implants (102 implants; mean implant
time, 95 months) treated at our center between 1990 and
2010 for osteomyelitis. Six patients were lost to followup.
The reason for amputation was tumor, trauma, or ischemia
in 97 limbs and infection in five. All patients were referred
from other orthopaedic centers owing to difficulty with use
or to be fitted with socket prostheses. If found ineligible for
this implant procedure no other treatment was offered at
our center. Osteomyelitis was diagnosed by medical
chart review of clinical signs, tissue culture results, and
plain radiographic findings. Proportion of daily prosthetic
use when osteomyelitis was diagnosed was semiquantita-
tively graded as 1 to 3. Survivorship free from implant-
associated osteomyelitis and extraction attributable to
osteomyelitis respectively was calculated using the
Kaplan-Meier estimator. Indication for extraction was
infection not responsive to conservative treatment with or
without minor de´bridement or loosening of implant.
Results Implant-associated osteomyelitis was diagnosed
in 16 patients corresponding to a 10-year cumulative risk of
20% (95% CI 0.12–0.33). Ten implants were extracted
owing to osteomyelitis, with a 10-year cumulative risk of
9% (95% CI 0.04–0.20). Prosthetic use was temporarily
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impaired in four of the six patients with infection who did
not undergo implant extraction. With the numbers avail-
able, we did not identify any association between age,
BMI, or diabetes with osteomyelitis; however, this study
was underpowered on this endpoint.
Conclusion The increased risk of infection with time
calls for numerous measures. First, patients should be made
aware of the long-term risks, and the surgical team should
have a heightened suspicion in patients with method-
specific presentation of possible infection. Second, several
research questions have been raised. Will the surgical
procedure, rehabilitation, and general care standardization
since the start of the program result in lower infection
rates? Will improved diagnostics and early treatment
resolve infection and prevent subsequent extraction?
Although not supported in this study, it is important to
know if most infections arise as continuous bacterial
invasion from the skin and implant interface and if so, how
this can be prevented?
Level of Evidence Level IV, therapeutic study.
Introduction
Patients with transfemoral amputations traditionally have
been treated with a prosthesis incorporating a socket in
which the residual limb is placed, along with some form of
supportive girdle to permit motion and secure fit. For many
patients socket use is complicated by loading pain or sitting
discomfort, contact dermatitis or sores, and reduced ROM
[15]. In addition, patients with short stumps may have
difficulty with fit and function. As a result of these issues,
Bra˚nemark et al. [9] expanded the application of osseoin-
tegrated dental implants [7] to limb replacement for
patients unable to be fitted with, or use a socket.
Osseointegration is recognized as the approximation of the
implant titanium oxide surface and bone tissue with no
interposition of fibrous tissues [12]. Briefly, the surgical
method involves a threaded titanium cylinder (fixture)
inserted in the medullary cavity of the residual bone.
Undisturbed integration is allowed for 6 months before a
skin-penetrating extension (abutment) is inserted in the
fixture (Fig. 1), serving as an anchor site for the external
prosthesis. This is followed by a carefully designed reha-
bilitation program [16]. There is no skin attachment to the
abutment, thus it can be replaced if bent or damaged. In
selected patients with amputation (mainly attributable to
trauma and tumor), the method results in improved pros-
thesis handling and limb control, eliminates socket-caused
skin disorders, and improves quality of life [17, 26, 42].
Overall cost effectiveness compared with socket-suspended
prostheses is not known, but annual mean prosthetic
workshop costs are similar [18]. The principle is well
established in the prosthetic replacement of teeth [7] and in
craniofacial reconstruction [14]. In lower limb replacement
a few modular methods [9, 23, 43] were developed after the
first orthopaedic implantation by Per Ingvar Bra˚nemark
and Bjo¨rn Rydevik in 1990 [9]. The use of biomedical
implants involves a risk of infection, particularly if the skin
barrier is penetrated. Bacterial adhesion with subsequent
biofilm formation are considered central in foreign-body
infection and in the compromised tissues of other chronic
infections [11]. Most bacteria have these properties, but
coagulase-negative staphylococci and Staphylococcus
aureus dominate in human implant infections [1, 24]. Other
important biofilm-producing bacteria include Enterococcus
faecalis and Propionibacterium acne [20, 30]. Risk factors
for prosthetic joint infections include diabetes, rheumatoid
arthritis, renal failure, malnutrition, immunosuppression,
wound infection, and the nasal carriage of S aureus [5].
Obesity has been shown to be an independent risk factor
for periprosthetic infection [32]. Smoking is detrimental to
bone healing and diabetes appears to impede osseointe-
gration [4, 19, 29, 37]. At our center, preoperative selection
includes ruling out patients with suspected infection, and
diagnostic biopsies have been introduced to this end.
Bacteria may enter deep tissues at implantation, through
the skin breach, the central screw canal of the fixture, or by
the hematogenous route, theoretically making this method
vulnerable to superficial and deep infection. However, the
proximal end of the fixture is sealed by the air-tight central
screw (which can be removed for marrow blood sampling)
and adequate osseointegration counteracts bacterial spread
along the outer threads of the fixture [9, 10]. Titanium
interacts more favorably with surrounding bone than con-
ventionally used implant metals. This appears to reduce the
risk of bone infection [13, 38].
Overall outcome for the first 100 patients with a trans-
femoral amputation indicated a higher success rate with
newer treatment protocols and greater surgical experience,
but failures relating to infections were not systematically
evaluated [16]. Branemark et al. [8] reported that four of 51
patients experienced a deep infection during a 2-year per-
iod. Previous prospective data from our center in a similar
but smaller cohort suggested that 18% of patients have an
implant-associated deep infection during a 3-year period
[40]. Many of these infections showed little inflammatory
activity and involved only limited and temporary loss of
function for the patient [40]. S aureus was slightly more
common than coagulase-negative staphylococci followed
by Enterococcus spp. in diagnostic cultures.
This method, intended for life-long prosthetic limb
support, is potentially vulnerable to infection limiting its
usefulness. Therefore, we aimed to (1) quantify the risk of
osteomyelitis, (2) characterize the clinical effect of
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osteomyelitis (including the risk of prosthesis extraction
and impairments to function), and (3) determine whether
common patient factors (age, sex, body weight, diabetes,
and implant component replacements) are associated with
osteomyelitis in patients with transfemoral amputations
treated with osseointegrated titanium implants.
Patients and Methods
We performed a retrospective cohort study of the first 96
patients with transfemoral amputations selected for treat-
ment with 102 (six bilateral) intramedullary transcutaneous
titanium implants at our osseointegration center in
Gothenburg between May 1990 and January 2010
(Table 1). All patients were referred from other Swedish or
European centers owing to difficulty to use (socket com-
plications) or be fitted with (stump malformation) a socket
prosthesis. No alternative treatment was offered at our
center for the approximately one-third of the patients who
were not found suitable for implant surgery in team eval-
uation. Twenty-seven patients had their implants before the
start of a systematic treatment and rehabilitation protocol
(Osseointegrated Prostheses for the Rehabilitation of
Amputees [OPRA]), yielding prospective, nonrandomized
results on overall outcome and patient-centered function
[8] in January 1999. Fifty-one patients were treated in the
OPRA study, and 18 were treated after that, without any
protocol alterations. Ninety-one patients underwent
amputation owing to tumor, trauma, or an ischemic event,
and five underwent amputation because of primary deep-
seated infection. Apart from eight patients (six with
diabetes and peripheral artery disease, one with severe
neurofibromatosis, one with cytostatic treatment), all
patients were free from other major illnesses at the time of
implant surgery. Limbs were grouped according to a pre-
viously suggested standard of residual lengths [34].
The time from implant insertion to the diagnosis of
osteomyelitis and/or extraction caused by infection was
registered. The mean observation time in the study was
7.9 years (median, 6.2 years; range, 1.5–19.6 years).
Diagnoses were based on careful examinations of patient
records, culture results [3], and plain radiographs (Fig. 2)
examinations. Osteomyelitis was defined as evidence of
Table 1. Basic demographics at implant surgery
Demographic Value
Number of patients (men/women) 96 (60/36)
Number of implants (bilateral implants) 102 (6)
Reasons for amputation: tumor/trauma/ischemia/
infection/other
20/71/5/5/1
Time since amputation, mean (range) 11.5 (\ 1–44)
years
Age, mean (range) 43.5 (19–65)
years
BMI, mean (range)* 26 (16-43)
kg/m2
Number of smokers 22
Number of patients with diabetes (insulin
dependent)
6 (3)
Residual limb lengths, short/normal/long 34/60/8
*Thirteen patients had Class I obesity (BMI 30–34.9 kg/m2) and four
had obesity Classes 2 and 3 (BMI, 35 to C 40 kg/m2).
Level referred to in osteomyelitis.
Level referred to in distal osteitis.
Fig. 1 The schematic shows
the implant components and
tissues of the femoral residual
limb. The level of implant-asso-
ciated osteomyelitis and distal
osteitis respectively, is indicated
by brackets. (Published with
permission from Cecilia Berlin
PhD, Chalmers University of
Technology, Gothenburg, Swe-
den. Illustration licensed under
Creative Commons BY 4.0.).
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infection involving implant-surrounding bone and/or bone
marrow, supported by positive percutaneous bone biopsy
or aspirated bone marrow cultures, and classified as defi-
nite, probable, or possible (Table 2). The definitions are
based on diagnostic algorithms for prosthetic joint infec-
tions [3, 39]. Infections were considered resolved if
patients were symptom-free 12 months or more after dis-
continuation of antibiotics. Bone marrow is accessible via
the normally screw-sealed proximal end of the intrame-
dullary component. Peripheral blood cultures were not
routinely taken. Indication for extraction was infection not
responsive to conservative treatment or loosening evident
in stability testing of the implant. Eight patients were right-
censored in the implant survival analyses for reasons other
than study completion (five for noninfected implant
extractions [including reimplantations]; one lost to fol-
lowup; one with a retained fixture and sealed skin; and one
death not related to the implant). Local signs of infection
and bone attrition rather than osteolysis in the femoral shaft
distal to the fixture were difficult to define. Microbial
involvement was highly suspected, but an etiologic diag-
nosis (ie, bacterial osteitis) was unattainable owing to lack
of reliable tissue cultures. This distal osteitis was separately
registered. Prosthetic use at the time of osteomyelitis was
retrospectively assessed by a team physiotherapist (KH)
and assigned a simple 1 to 3 score (unchanged = 1,
impaired = 2, and no prosthetic use owing to infec-
tion = 3). Patients still in the early postoperative
rehabilitation phase (the first months before use of the
prosthesis in daily life) at the time of the infection were not
assessed in terms of impaired prosthetic use.
Furthermore, the total number of short courses of oral
antibiotics for superficial infection in each patient was
recorded. There was concern that pressure-induced bone
marrow contamination could occur during the exchange of
abutments and all exchanges therefore were recorded.
Previously identified risk factors for impaired bone-implant
healing and infection common in this cohort (ie, smoking,
diabetes, [high] BMI, and age), were compiled from
chart review and analyzed for association with
osteomyelitis [4, 5, 19, 29, 32, 37].
Statistics
Statistical end-points were first implant osteomyelitis and
first implant extraction owing to infection. We used the
Kaplan-Meier estimator to calculate the risk of
osteomyelitis and extraction with time. Based on data at the
time of implant insertion, risk factor correlation was per-
formed with the Cox proportional hazard model. A hazard
ratio (HR) for cumulative abutment replacements was
obtained by time-modified Cox analysis. Differences were
considered significant at a probability less than 0.05. Data
Table 2. Definitions of osteomyelitis around the implant system
Type of infection Signs and
symptoms*
Positive tissue
cultures
Positive
radiograph#
Definite implant
infection
Yes Yes Yes
Probable implant
infection
Yes Yes Yes
Possible implant
infection
Yes No Yes
*Loaded/unloaded pain, stump swelling, and purulent secretion with
or without visible skin inflammation in the skin penetration area; 
intraoperative cultures where C 2 of 5 yielded identical bacteria;
intraoperative cultures not meeting criteria; #radiographic evidence
of osteolysis with or without periosteal sclerosis around a previously
integrated implant. In acute infection, negative findings were
disregarded.
A B
Fig. 2A–B (A) AP and (B) lateral view plain radiographs show small
zones of radiolucency (arrows) between the implant and bone in a
male patient with osteomyelitis around an osseointegrated implant in
the left femur. Free projection of the implant threads is important for
correct evaluation.
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were computed with the GraphPad Prism 6 (GraphPad
Software Inc, San Diego, CA, USA) and SAS (SAS Insti-
tute Inc, Cary, NC, USA) statistical software.
Results
Long-term Risk of Osteomyelitis
By 10 years the estimated risk of osteomyelitis reached 20%
(95% CI, 0.12–0.33) (Fig. 3). After that, the number of
patients at risk was too low, making further estimation
uncertain. The median time from implantation to
osteomyelitis was 2.6 years (range, 0.3–13.8 years). During
the entire 20-year study period, 16 patients (16 implants) had
osteomyelitis (12 definitive, three probable, one possible)
develop, which in 10 instances led to extraction of the
implant translating to a 10-year cumulative risk of 9% (95%
CI, 0.04–0.20). Seven of these patients were treated before
the OPRA protocol. Osteomyelitis developed in five of 34
short stumps (15%), while figures for normal and long
stumps were 10 of 60 (17%) and one of eight (13%). Six
patients (one with bilateral implants) without definable
osteomyelitis had signs of distal osteitis, as defined above,
corresponding to an 8% (95%CI, 0.02–0.24) risk at 10 years
of implant use (Fig. 2). No distal osteitis was clinically
recognized before the 5-year followup after implant insertion
(mean, 125.5 months; range, 64–192 months) and in the
patient with bilateral implants, as late as 14 and 16 years
respectively. Microbial involvement was highly suspected,
but in the absence of reliable tissue cultures and histologic
analyses, an etiologic diagnosis (ie, bacterial osteitis) was
unattainable.
Clinical Effect of Osteomyelitis
Of the 16 patients with a diagnosis of osteomyelitis, 10
required removal of the implant for complete recovery
(Table 3). The clinical presentation of osteomyelitis varied,
being either subacute or acute (eight patients), including one
patient with mild septicemia, or chronic with or without
fistulas (eight patients). There was a wide range in prosthetic
use at the time of diagnosis of osteomyelitis. Two patients
(later implant extraction in one) were unable to use their
prostheses, six had moderately restricted prosthetic use
(three implants extracted), and two had no impairment (no
implant extracted). The remaining six patients were in the
early rehabilitation phase and therefore could not be as-
sessed. In this group, all six implants were extracted between
4 to 102 months (median, 25 months) from fixture insertion.
In four patients, osteomyelitis was resolved with antibiotics
without extracting the implant. Three of these patients had a
staphylococcal infection and received a rifampin-based
treatment. S aureus and coagulase-negative staphylococci
were the most common bacteria isolated in intraoperatively
obtained cultures (Table 4). In one patient, S aureus was
isolated from peripheral blood after an episode of fever but
no signs of severe sepsis such as manifest hypotension or
organ dysfunction developed. In patients with distal osteitis
the clinical course wasmilder, and none of the implants were
extracted in this group. In five of six patients (seven
Table 4. Bacterial yield by intraoperative bone or marrow cultures in
patients with osteomyelitis
Bacteria Number of
isolates*
Staphylococcus aureus, including one case of
methicillin-resistant S aureus
9
Coagulase-negative staphylococci, including one
case of Staphylococcus lugdunensis
4
Enterococcus faecalis 2
Escherichia coli 1
Proteus mirabilis 1
Peptostreptococci 1
Pseudomonas aeruginosa 1
Negative 1
*In four infections, two bacterial species were isolated and in one,
reliable cultures were lacking.
Table 3. Clinical outcome for patients classified as having
osteomyelitis during the study period
Recovery after
antibiotics
with or
without minor
de´bridement
(number of
patients)
Recovery
and later
relapse
(number of
patients)
Successful
reimplantation
(number of
patients)
Recovery
after
extraction
(number of
patients)
Chronic
with
fistula
(number
of
patients)
4 1 1 9 1
Fig. 3 The graph shows the probability, with 95% CIs, of
osteomyelitis and extraction owing to osteomyelitis with time.
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implants) considered to have distal osteitis, skin infection
was present at diagnosis and all had various other skin
problems (ie, fibrous hyperplasia, hyperkeratosis, and
ulcers). Three had unrestricted and three had moderately
impaired prosthetic use at the time of diagnosis. The mean
use of short-course antibiotics in patients with distal osteitis
(mean number of courses, 21.5; range, 10–30) was more
frequent (p\ 0.01) compared with that of patients later
diagnosed with implant infection (mean number of courses,
6; range, 0–15).
Patient Factors Examined for Association With
Osteomyelitis
With the numbers available, we found no association
between selected patient factors and osteomyelitis. An
increase in replacement of abutments was not related to
implant infection (HR, 1.13; p = 0.16), and no risk increase
was seen in patients who were overweight (BMI[ 25 kg/
m2) (HR, 0.99; 95% CI, 0.90–1.09; p = 0.97), elderly (HR,
0.98; 95% CI, 0.96–1.02; p = 0.75), or who smoked (HR,
1.8; 95%CI, 0.69–4.73; p = 0.22) during the time of implant
surgery. Furthermore, there was no sex difference (HR, 0.92;
95% CI, 0.39–2.17; p = 0.85) or risk increase in patients
with uncomplicated diabetes at the time of implant insertion
(HR, 2.70; 95% CI, 0.78–9.39; p = 0.11).
Discussion
In individuals with transfemoral amputations, especially
with a short or malformed residual limb, socket prostheses
cause substantial disadvantages for many including dis-
comfort, skin problems, and poor function. These problems
are reduced substantially when the prosthetic limb is
attached to a percutaneous osseointegrated implant. How-
ever, the long-term risk of implant-associated infection and
its clinical effect are not known with this method. In the
first 96 patients treated with this novel method, we esti-
mated that the cumulative risk of implant-associated
osteomyelitis was 20% and the risk of implant extraction
attributable to infection was 9% during a 10-year implant
period. In four of the six patients for whom infection did
not lead to extraction, prosthetic use was impaired. Reso-
lution of osteomyelitis was attainable with prolonged
combined antibiotics in one-quarter of the patients.
Limitations
Our study has several limitations. Comorbidities associated
with risk of poor healing and infection (arterial disease and
complicated diabetes) are underrepresented in the patient
cohort owing to preoperative selection. BMI, uncompli-
cated diabetes, and smoking were recorded only at the time
of implantation, and no adjustments were made owing to
changes in these variables with time which would only
permit detection of a very strong relationship. The data
were extracted retrospectively from medical charts by one
author (JT) and reexamined by all authors before being
added to the final dataset. We acknowledge the difficulty of
defining method-typical osteomyelitis. Our definitions,
although not validated, avoid excluding patients with cul-
ture-negative results with a high overall likelihood of
osteomyelitis. Any overestimation is likely small as
osteomyelitis was definite in 75% of the patients. Fur-
thermore, the reliability of the method-specific tissue
sampling is not known. Although less invasive than per-
cutaneous bone tissue biopsies, bone marrow aspirations
through the fixture possibly are more vulnerable to sample
contamination, and it is uncertain if multiple samples add
to diagnostic precision, as contaminants and true pathogens
alike disperse in the liquid phase. Functional impairment
could be graded only approximately owing to the 20-year
retrospective span. Six patients were lost to followup
including one patient with method-unrelated death, but all
patients from the early phase (1990–1998) of the method
development (custom-design period) have been included.
Since then, several modifications have been made leading
to standardized implants, surgical technique, and a strict
rehabilitation protocol. This may result in reduced infec-
tious complications. Outcome improvement also can be
expected with standardized diagnostic protocols and early
treatment with biofilm-effective antibiotics [6, 33, 36].
This method, intended for life-long prosthetic limb
support, is potentially vulnerable to infection limiting its
usefulness. However, we had no data with respect to very
long-term risk of osteomyelitis and the clinical effects
thereof. Previous outcome results not centering on infec-
tion indicate higher success rates with newer treatment
protocols and greater surgical experience [8, 16]. In the
current study, we found a high long-term risk of
osteomyelitis in a young (mean age at first surgery,
43.5 years) patient group with good health compared with
the average patient undergoing arthroplasty [41]. This
raises concerns regarding increasing risk of infection
attributable to aging and related morbidities. Lower
infection rates are needed before the indication can be
widened. Currently, this treatment is only offered when
socket prostheses are not an option, preexisting conditions
likely to increase risk for failure are ruled out, and patients
are made fully aware of the elevated risk of infectious
complications. The method has similarities to percutaneous
bone fixation and joint arthroplasty. In the latter, infection
rates have decreased dramatically since its introduction
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[25], with a 10-year cumulative incidence of approximately
1.5% to 2%, using standardized infection control measures
[39]. Frequent but limited osteitis in external pin fixation
[27] underscores how readily a percutaneous device pro-
motes infection. Beyond this however, differences in
surgical technique and tissue-material interaction do not
allow for meaningful comparison. Some investigators aim
for a microbial barrier by skin attachment to the percuta-
neous component [22, 35]. Conversely, our method aims to
minimize skin mobility and secondary inflammation [9], in
addition to allowing easy component replacements for the
patient and surgeon. S aureus was twice as common as
coagulase-negative staphylococci, likely because the skin
stoma in this method favors the invasion-prone S aureus
and not owing to a higher proportion of blood borne
inoculation [39].
Full or moderate prosthetic use was maintained in more
than half of the patients with infections not subjected to
later implant extraction. Our interpretation is that load-
bearing ossointegration can be preserved even in local
osteomyelitis, justifying attempts of conservative
treatment.
In a few patients, the infectious complications were
acute, involving bone and marrow, indicating blood seed-
ing from distant loci. That no patient had severe sepsis is
important. However, a method resulting in frequent use of
antibiotics contributes to bacterial resistance and increases
adverse drug events. A strict policy in perioperative
antibiotic prophylaxis and skin infection treatment will
partly address this issue. Based on time of diagnosis,
osteomyelitis develops later, and fewer implants are
removed owing to early infection with this method com-
pared with prosthetic joint infections [21, 28]. This likely
stresses the importance of good primary osseointegration,
translating to painless performance and possibly protection
against early infectious development [8]. The robustness of
the osseointegration and antiinfective properties of the
titanium (oxide) surface [2, 13] might explain the lack of
infectious problems for many patients despite the intimacy
between the skin microflora and the foreign material.
However, it is conceivable that diagnostic delay in part
explains the above, especially during rehabilitation, when
diffuse pain indirectly related to increased prosthetic
loading appears difficult to distinguish from pain caused by
osteomyelitis. From these observations, deep infection
should be suspected in rehabilitation that is delayed
because of pain, even in absence of other signs of infection.
Furthermore, low-grade infection can be very difficult to
distinguish from aseptic loosening, much like in arthro-
plasties [31]. Although not validated for our method, we
suggest that diagnostic algorithms based on clinical signs,
radiology, histopathology, and multiple tissue cultures
[3, 33] be used to aid in decision making. Patients with
distal osteitis were difficult to define as having implant-
associated infection or not. This was partly because tissue
culturing had been avoided owing to concern that it would
interfere negatively with tissue integration, and partly
because biomechanical bone wear was expected in this
region. Frequent antibiotic use in this group however,
suggests infectious bone degradation and supports appro-
priate culturing. It is not yet known whether distal osteitis
progresses to osteomyelitis involving proximal parts of the
implant system in the long term, but no such observation
was made in the current study. Whether distal osteitis
should be treated differently or at all therefore is not clear.
Prospective investigations are warranted.
In our cohort (age range, 19–65 years), increased age
did not appear to be a risk factor for infection, whereas
time since implantation clearly was. We were concerned
that exchanges of abutments after component failure might
cause bacterial contamination, but we found no correlation
between frequent abutment changes and infection. How-
ever, in four patients, there was a temporal relationship
between abutment change and the start of infectious com-
plications, which calls for prospective studies and strict
aseptic conditions while performing this procedure which
now have been implemented in our protocol. Only three
patients had insulin-dependent diabetes, and none of them
was severely obese. Therefore, it is not to be interpreted
that diabetes is a negligible risk factor in this method. It
might be expected that patients with a short residual limb
are more prone to infection owing to the rich bacterial flora
in the groin and a higher risk of implant instability and poor
tissue integration, but our data do not support these
assumptions.
Conclusion
The bone-anchored prosthesis using the osseointegration
technique substantially improves quality of life after a
transfemoral amputation [17]. The key question is whether
these advantages outweigh the risk of deep or recurring
superficial implant-associated infection.
We showed that the overall risk of implant
osteomyelitis in patients who receive percutaneous
osseointegrated implants after transfemoral amputation
increases with time. This is a major problem, as the
method is intended to be a lifetime solution for prosthetic
support. Infections which do not lead to implant removal
only moderately reduce prosthetic function, and with
more than 20 years’ experience with the method, we
believe that improved daily living outweighs the risks and
inconvenience of treatment for most patients [26] in this
respect. As in all other medical interventions, it is
important to inform patients regarding possible infectious
3106 Tillander Clinical Orthopaedics and Related Research1
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complications and the risk of implant extraction if severe
infectious complications occur. Will the surgical proce-
dure, rehabilitation, and general care standardization since
the start of the program result in lower infection rates?
Prospective studies are warranted. Will improved diag-
nostics guiding early treatment and better handling of
system components reduce infectious complications?
Although not directly supported in this study, continuous
bacterial invasion from the skin-implant interface as a
cause for osteomyelitis cannot be ruled out. Further
studies of method-specific diagnostics and treatment,
bacterial properties, and characteristics of the skin-pene-
tration area should be done to address these issues.
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